December 8, 2025BloodOpen Access

Real world outcomes of patients with cold agglutinin disease

View Full Paper

Ask AI

Bookmark

Authors

NJNicole JapzonUniversity College Hospital RBRobert Baker RGRajeev GuptaCancer Institute (WIA)

Discussion

Member takes

Implication

Retrospective analysis shows response rates of over 50% in cold agglutinin disease patients with rituximab and complement therapies, indicating effective disease management.

Key Points

Cold agglutinin disease patients experienced significant treatment response rates exceeding 50% using rituximab-based therapies.
The study included 54 patients, revealing a median overall survival of over 14 years and impressive 3-year and 5-year overall survival rates of 93% and 86%, respectively.
Retrospective analysis from a referral center assessed treatment patterns and survival data in patients diagnosed between 2016 and 2023.
These findings support the use of directed therapy and monitoring in managing cold agglutinin disease effectively.

Cite This Study

Japzon et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236dac4 https://doi.org/10.1182/blood-2025-4677

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis shows response rates of over 50% in cold agglutinin disease patients with rituximab and complement therapies, indicating effective disease management.

Real world outcomes of patients with cold agglutinin disease

Discussion

Member takes

Implication

Key Points

Cite This Study

Real world outcomes of patients with cold agglutinin disease

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider